Conjugate comprising a folic acid antagonist and a carrier

Details Conjugate comprising a folic acid antagonist and a carrier Conjugate comprising a folic acid antagonist and a carrier

2000-07-13

2004-04-13

Low, Christopher S. F. (Department: 1653)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S012200, C514S249000, C514S564000, C530S324000, C530S350000, C530S810000, C530S816000, C424S009100, C544S258000, C544S260000

Reexamination Certificate

active

06720304

ABSTRACT:

I. FIELD OF THE INVENTION
The invention relates to a conjugate comprising a folic acid antagonist and a carrier, a method for the production of such a conjugate as well as it's use.
II. BACKGROUND OF THE INVENTION
Folic acid is a compound present in nature which is important in cells for methyl group transfer and thus for the growth of cells. Folic acid has the following formula:
The CH group of the glutamic acid represents an asymmetric C atom. Therefore, folic acid exists in two enantiomeric forms, namely as D- and L-enantiomers.
However, only the L-enantiomer from these enantiomeric forms is found in cells, so that only this form, but not the D-enantiomer, is responsible for the action of folic acid. The reason for this is that folic acid is taken up in cells by the foliate receptor, which however only takes up the L-enantiomer, but not the D-enantiomer, of folic acid.
Folic acid antagonists are compounds which are derivative from folic acid but counteract the latter at its target area, namely in cells. Therefore, folic acid antagonists are present as L-enantiomers but not as D-enantiomers. Examples of folic acid antagonists are aminomopterin and amethopterin which is also designated as methotrexate.
Methotrexate, i.e., the L-enantiomer of amethopterin, is frequently employed for the treatment of tumors and inflammations. However, major side-effects have been demonstrated for this because methotrexate is also taken up by healthy tissue and is toxic for it DE-A-41 22210.5 alone describes conjugates of methotrexate and albumin which are taken up better by tumors than by healthy tissue and are thus less toxic. Nevertheless, a great need exists for agents which have even weaker side-effects.
Therefore, the object of the present invention is to provide an agent for the treatment of diseased tissues, especially tumors, which has the weakest side-effects.
III. SUMMARY OF THE INVENTION
The invention relates to conjugates comprising a D-enantiomer of a folic acid antagonist and a carrier. Furthermore, the invention relates to the production of such conjugates as well as their use.


REFERENCES:
patent: 44 33 890 (1996-03-01), None
patent: 0 251 455 (1988-01-01), None
patent: WO 85/00812 (1985-02-01), None
patent: WO 93/15751 (1993-08-01), None
Schulz et al., REactions of polymer analogs with methotrexate, Z. Chem. (1987) 27(12):437-438.*
Zalipsky et al., Poly(Ethylene Glycol) Chemistry: Biotechnical and Biomedical Applications, J. Milton Harris, ed., Plenum Press, NY (1992) pp. 347-370.*
Frei et al., 1997, “Cellular uptake and method of methotrexate bound to albumin differs from that of free methotrexate,”Proceedings of the American Association of Cancer Research Annual Meeting, Eighty-Eighth Annual Meeting of the American Association for Cancer Research, San Siego CA. Apr. 12-16, 1997, vol. 38, p. 432.
Jackman et al., 1993, “Gamma-linked dipeptide analgoues of 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolate as antitumour agents,”Adv. Exp. Med. Biol. 338: 579-584.
Lee et al., 1974, “Folic acid antagonists. Methotrexate analogs containing spurious amino acids. Dichlorohomofolic acid,”J. Med. Chem. 17(3):326-330.

Affiliated with

Also associated with

Rating

Conjugate comprising a folic acid antagonist and a carrier does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Conjugate comprising a folic acid antagonist and a carrier, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Conjugate comprising a folic acid antagonist and a carrier will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3218982